Share-based Payment Arrangement, Expense of Athira Pharma, Inc. from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Athira Pharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • Athira Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,410,000, a 52% decline year-over-year.
  • Athira Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $6,873,000, a 38% decline year-over-year.
  • Athira Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $11,049,000, a 4% increase from 2023.
  • Athira Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $10,623,000, a 0.16% increase from 2022.
  • Athira Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,606,000, a 129% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Athira Pharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,873,000 $1,410,000 -$1,526,000 -52% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $8,399,000 $1,597,000 -$1,608,000 -50% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $10,007,000 $1,637,000 -$1,042,000 -39% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $11,049,000 $2,229,000 +$1,000 +0.04% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $11,048,000 $2,936,000 +$442,000 +18% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $10,606,000 $3,205,000 +$86,000 +2.8% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $10,520,000 $2,679,000 -$103,000 -3.7% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 $10,623,000 $2,228,000 -$132,000 -5.6% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $10,755,000 $2,494,000 +$74,000 +3.1% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $10,681,000 $3,119,000 +$24,000 +0.78% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $10,657,000 $2,782,000 +$51,000 +1.9% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $10,606,000 $2,360,000 +$925,000 +64% 01 Oct 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
Q3 2022 $9,681,000 $2,420,000 +$1,315,000 +119% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $8,366,000 $3,095,000 +$1,986,000 +179% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $6,380,000 $2,731,000 +$1,757,000 +180% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $4,623,000 $1,435,000 +$1,020,000 +246% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $3,603,000 $1,105,000 +$994,000 +895% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $2,609,000 $1,109,000 +$1,060,000 +2163% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $1,549,000 $974,000 +$916,000 +1579% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $633,000 $415,000 01 Oct 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
Q3 2020 $111,000 +$42,000 +61% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $49,000 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $58,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q3 2019 $69,000 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3

Athira Pharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $11,049,000 +$426,000 +4% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $10,623,000 +$17,000 +0.16% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $10,606,000 +$5,983,000 +129% 01 Jan 2022 31 Dec 2022 10-K 22 Feb 2024 2023 FY
2021 $4,623,000 +$3,990,000 +630% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $633,000 +$380,000 +150% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
2019 $253,000 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.